ABIOMED, Inc. (NASDAQ:ABMD) is now up 18.59% compared to a 12-month low of $228. We have seen the price to move 2.95% higher and get settled at $270.39 on 5/24/2019. At recent session, it appeared stuck in a range of $262.83 to $272.79. This company shares are 24.72% off its target price of $337.22 and the current market capitalization stands at $11.85B. The recent change has given its price a -3.23% deficit over SMA 50 and -41.19% deficit over its 52-week high. The stock witnessed 0.84% gains, -23.38% declines and -10.55% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ABMD’s volatility during a week at 3.25% and during a month it has been found around 4.15%.

ABIOMED, Inc. (ABMD) Top Holders

Institutional investors currently hold around $10.79 billion or 89.7% in ABMD stock. Look at its top three institutional owners: Vanguard Group Inc owns $1.31 billion in ABIOMED, Inc., which represents roughly 11.09% of the company’s market cap and approximately 12.18% of the institutional ownership. Similar statistics are true for the second largest owner, Primecap Management Co/Ca/, which owns 3,149,040 shares of the stock are valued at $851.47 million. The third largest holder is Blackrock Inc., which currently holds $838.03 million worth of this stock and that ownership represents nearly 7.07% of its market capitalization.

ABIOMED, Inc. 13F Filings

At the end of March reporting period, 300 institutional holders increased their position in ABIOMED, Inc. (NASDAQ:ABMD) by some 3,857,066 shares, 242 decreased positions by 3,677,818 and 70 held positions by 32,368,099. That puts total institutional holdings at 39,902,983 shares, according to SEC filings. The stock grabbed 84 new institutional investments totaling 538,206 shares while 54 institutional investors sold out their entire positions totaling 1,139,496 shares.

ABIOMED, Inc. (NASDAQ:ABMD) Insider Trades

Multiple company employees have indulged in significant insider trading. ABIOMED, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director SUTTER MARTIN P has sold 4,664 shares of ABIOMED, Inc. (ABMD) in the trading session dated May. 08, 2019. These shares are worth $1,212,500 and were traded at $259.97 each. The SEC filing shows that SUTTER MARTIN P performed a sale of 20,000 shares. The Director disposed these shares by way of transaction on Feb. 15, 2019. The company’s shares were given away at $360.16 per share worth to an income of some $7,203,200 to the account of SUTTER MARTIN P.

Director, SUTTER MARTIN P, sold 30,000 common shares of ABIOMED, Inc. (ABMD) in the open market. In a transaction dated Feb. 06, 2019, the shares were put up for sale at an average price of $350.09, raking in a sum of $10,502,700. After this sale, 200,491 common shares of ABMD are directly owned by the insider, with total stake valued at $54,210,761.

In the transaction dated Jan. 25, 2019, a great number of shares sold came courtesy the COO; Weber David M disposed a total of 24,000 shares at an average price of $351.47, amounting to approximately $8,435,280. The insider now directly owns 163,339 shares worth $44,165,232.

ABIOMED, Inc. (ABMD) Analyst Guide

Several analysts have released their opinion on ABIOMED, Inc. (NASDAQ:ABMD), with 6 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 3 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.33 average brokerage recommendation [T1].